Thank
you for making 2004 such a wonderful year for the PH Community!
With your support, more reseatch
is being done on PH, more treatment options are available than
ever before, and there is ever-increasing hope in the search
for a cure.
Read more about all the advances
made in 2004 in PHA's annual report..
Families reflect on ultimate gift, An organ donation is a bequest that keeps giving
When Jean Swartling, of Sun Valley, took on a hiking trip to Italy in 1996 she went without realizing she was already suffering from Primary Pulmonary Hypertension, a disease which constricts the blood vessels going to the lungs thus depriving them of oxygen. In 2000 she received the first of the two cadaveric lungs. Unfortunately, with her defenses already low, she became sick shortly afterwards and required a second transplant, which she received two years later. Without a transplant, she was given approximately two to five years to live. She was 61 at the time.
New Imaging Technique Helps Researchers Probe Lung Vessel Changes Linked to Deadly Hypertension
MILWAUKEE, Dec. 13 (AScribe Newswire) -- A team of researchers from the Medical College of Wisconsin, Marquette University and the VA Medical Center-Milwaukee has introduced a promising new technique to study the arteries of the lungs and their role in pulmonary hypertension.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
Pfizer submits regulatory filings for Revatio (sildenafil citrate) as a treatment for pulmonary arterial hypertension
"The regulatory filings for sildenafil usage in PAH demonstrate Pfizer's commitment to address unmet medical conditions by exploring new uses for our existing medicines, together with our significant efforts to discover and develop new compounds," said Joseph Feczko, M.D., president of Worldwide Development. "PAH is a condition for which new treatment options are desperately needed."
The "PHenomenal
Hope" wristbands
are going fast and helping to increase visibility of the PH community,
with patients including them with holiday gifts, young people taking
them to school, and so much more! Available in quantites of 10 (10
wristbands for $10), give
several away to your
friends and
family
members.
For
larger quantites, simply enter 2 for 20, 5 for 50, 10 for 100, etc.
Ventavis is an inhaled formulation of
iloprost, a synthetic compound that is structurally similar to prostacyclins- naturally
occurring molecules that cause blood vessels to dilate. A new drug
Application for Ventavis has been granted priority review by the U.S.
FDA, with an expected action date of December 31, 2004. The FDA also
has designated Ventavis as an orphan drug for the treatment of PAH.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
The "PHenomenal
Hope" wristbands
are going fast and helping to increase visibility of the PH community,
with patients including them with holiday gifts, young people taking
them to school, and so much more! Available in quantites of 10 (10
wristbands for $10), give
several away to your
friends and
family
members.
For
larger quantites, simply enter 2 for 20, 5 for 50, 10 for 100, etc.
